Arcus to raise $99M IPO; Vanda wants marketing approval for jet lag
→ Clinical-stage cancer immunotherapy maker Arcus Biosciences has set out to raise $99 million in an IPO, offering 7.1 million shares at a price range …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
